Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT02890368 Terminated - Melanoma Clinical Trials

Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

Start date: September 2016
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts. Part 1 is the Dose Escalation phase and Part 2 is the Dose Expansion phase. The purpose of this study is to characterize the safety profile of TTI-621 and to determine the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor activity of TTI-621 will be evaluated in combination with other anti-cancer agents or radiation.

NCT ID: NCT02887196 Terminated - Breast Neoplasms Clinical Trials

Attitudes Toward Physical Activity and Nutrition Intervention During Cancer Treatment

CARE
Start date: December 2016
Phase:
Study type: Observational

Twenty-five women will be followed through their breast cancer treatment. The women will be asked to provide their opinions and desires for lifestyle intervention at different times throughout treatment. In addition, basic clinical data will be collected . The primary goal of this pilot study is to investigate the physical and behavioral changes that occur in patients receiving treatment for breast cancer.

NCT ID: NCT02876640 Terminated - Clinical trials for Anatomic Stage II Breast Cancer AJCC v8

Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer

Start date: March 16, 2018
Phase: Phase 1
Study type: Interventional

This phase 1b trial studies the biologic effect of 9cUAB30 on early stage breast cancer. 9cUAB30 is a retinoid X receptor (RXR)-selective retinoid that acts in a tissue selective manner with the goal of minimizing side effects, a necessary feature of agents under development for cancer prevention.

NCT ID: NCT02867644 Terminated - Breast Cancer Clinical Trials

Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer

HYCOREMA
Start date: November 17, 2016
Phase: N/A
Study type: Interventional

The hypothesis is to assess the contribution of conversational hypnosis on anxiety of patients who undergoing for a preoperative breast tracking and improve their care

NCT ID: NCT02863146 Terminated - Breast Cancer Clinical Trials

Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer

Start date: May 2015
Phase: N/A
Study type: Observational

HALACAP-1406 is a prospective single-centre non-interventional study assessing the refrigerant helmet use as medical device to prevent alopecia induced by eribulin (Halaven®) in the conditions of use specified in its marketing authorization. Eribulin will be used alone for the treatment of the patients having a locally advanced or metastatic breast cancer which have progressed after at least 1 chemotherapy regimen for their advanced stage.

NCT ID: NCT02834247 Terminated - Clinical trials for Carcinoma, Non-Small-Cell Lung

A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors

Start date: August 12, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.

NCT ID: NCT02833766 Terminated - Breast Cancer Clinical Trials

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

Start date: October 28, 2016
Phase: Phase 2
Study type: Interventional

The main objective of the trial is to determine the efficacy of doxorubicin-loaded anti-EGFR immunoliposomes as first-line therapy in patients with advanced triple Negative, EGFR positive breast cancer. In this proof of concept trial, all patients will have an administration of the doxorubicin-loaded anti-EGFR immunoliposomes (anti-EGFR-IL-dox) every 28 days, until progression or unacceptable toxicity.

NCT ID: NCT02826512 Terminated - Breast Cancer Clinical Trials

A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients

Start date: May 15, 2018
Phase: Phase 2
Study type: Interventional

Patients with locally recurrent BRCA1-like, HER2-negative breast cancer that cannot be treated with curative intent by local treatment (surgery, radiotherapy +/- hyperthermia) or patients with metastatic BRCA1-like, HER2-negative breast cancer that have received a maximum of one prior line of treatment for incurable disease will be treated with Niraparib until disease progression

NCT ID: NCT02824575 Terminated - Breast Cancer Clinical Trials

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Start date: July 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of rebastinib when combined with antitubulin therapy with paclitaxel or eribulin in patients with advanced breast cancer.

NCT ID: NCT02823262 Terminated - Breast Cancer Clinical Trials

A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older

Start date: July 2016
Phase: N/A
Study type: Interventional

The purpose of this research study is to evaluate a decision aid to help women aged 70 and older decide on treatment for their breast cancer.